{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
First approved in 2016
Source:
PROTOXIN by PROTOX Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA101322
(1967)
Source URL:
First approved in 1967
Source:
BLA101322
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03857425: Phase 4 Interventional Completed Gastritis
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE